SanegeneBio, Genentech Partner on RNAi Therapeutics Development
SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, announced a global licensing agreement with Genentech, a member of the Roche Group, to advance one of its RNAi programs based on its proprietary RNAi platform. Under the agreement, SanegeneBio grants Genentech exclusive worldw…
